

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Scrip Code: 542650

Head Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051.
Scrip Symbol: METROPOLIS

Subject: Outcome of the Board Meeting held on August 11, 2020

Reference: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('LODR')

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held today through video conferencing have *inter-alia*:

1. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2020 and took note of the Limited Review Report issued by the Statutory Auditors of the Company on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2020;

The copy of the Unaudited Standalone and Consolidated Financial Statements of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter ended June 30, 2020 is enclosed as **"Annexure-1"**.

2. Approved the acquisition of balance Equity stake of 35% i.e. 10,50,000 Equity shares of Rs.10/- each in Metropolis Histoxpert Digital Services Private Limited ('Histoxpert').
3. Approved the acquisition of balance Equity stake of 49% i.e. 8,894 Equity shares of Rs.10/- each in Raj Metropolis Healthcare Private Limited ('Raj Metropolis').

The details required in respect of the above point nos. 2 and 3 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as **"Annexure-2"**.

The above meeting commenced at 2.10 p.m. and concluded at 4.05 p.m.

Thanking you,
Yours faithfully

For **Metropolis Healthcare Limited**

Poonam Tanwani
Company Secretary & Compliance Officer
Membership No. A19182
Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on unaudited quarterly standalone financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited ("the Company") for the quarter ended 30 June 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

B S R & Co (a partnership firm with
Registration No. BA61223) converted into
B S R & Co. LLP (a Limited Liability Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011, India

Limited Review Report on unaudited quarterly standalone financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (*Continued*)

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022

TARUN K
KINGER

Digitally signed by

TARUN K KINGER

Date: 2020.08.11

14:35:16 +05'30'

Tarun Kinger

Partner

Mumbai
11 August 2020

Membership No: 105003
ICAI UDIN: 20105003AAAACF3902



Statement of Standalone Financial Results for the quarter ended 30 June 2020

Sr. No.	Particulars	(Rs. in Lakhs)			
		Quarter ended		Year ended	
		30 June 2020 (Unaudited)	31 March 2020 (Audited) (Refer Note 5)	30 June 2019 (Unaudited)	31 March 2020 (Audited)
1	Income				
	a) Revenue from operations	11,077.74	16,315.52	15,695.94	66,530.71
	b) Other income	237.39	2,572.12	82.71	2,931.79
	Total Income	11,315.13	18,887.64	15,778.65	69,462.50
2	Expenses				
	a) Cost of material consumed	3,161.66	4,245.74	3,948.22	16,724.71
	b) Laboratory testing charges	35.85	211.78	135.91	649.76
	c) Employee benefits expense	3,616.27	3,493.90	3,650.06	14,766.62
	d) Finance costs	132.70	159.81	145.73	656.01
	e) Depreciation and amortisation expense	762.65	847.74	671.68	3,084.51
	f) Other expenses	3,398.95	4,668.74	3,843.68	17,129.15
	Total Expenses	11,108.08	13,627.71	12,395.28	53,010.76
3	Profit before exceptional item and tax (1) - (2)	207.05	5,259.93	3,383.37	16,451.74
4	Exceptional items (refer note 3)	-	1,766.18	686.48	2,452.66
5	Profit before tax (3) - (4)	207.05	3,493.75	2,696.89	13,999.08
6	Tax expenses				
	Current tax	197.00	1,649.70	825.65	3,933.00
	Deferred tax (income)/expense	(150.35)	(902.12)	39.27	(909.62)
	Tax adjustments for earlier years	(58.71)	(229.73)	-	(229.73)
	Total tax (income)/expenses	(12.06)	517.85	864.92	2,793.65
7	Profit for the period / year (5) - (6)	219.11	2,975.90	1,831.97	11,205.43
8	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(37.73)	(36.87)	7.46	(150.91)
	Other comprehensive (loss) / income for the period / year (net of tax)	(37.73)	(36.87)	7.46	(150.91)
9	Total comprehensive income (7) + (8)	181.38	2,939.03	1,839.43	11,054.52
10	Paid-up equity share capital (face value - Rs. 2 per share)	1,013.63	1,012.61	1,003.57	1,012.61
11	Other equity				50,225.85
12	Earnings per share (of Rs.2 each) basic - (Rs.)	0.43*	5.93*	3.65*	22.32
	Earnings per share (of Rs.2 each) diluted - (Rs.)	0.43*	5.90*	3.64*	22.22

(*not annualised)

See accompanying notes to the unaudited standalone financial results

NOTES:

- These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- The standalone financial results of the Company have been reviewed by the Audit Committee at their meeting held on 11 August 2020 and thereafter approved by the Board of Directors at their meeting held on 11 August 2020. The statutory auditors have expressed unqualified review opinion.
- Exceptional items comprises of:


Particulars	(in Rs Lakhs)			
	For the quarter ended 30 June 2020	For the quarter ended 31 March 2020	For the quarter ended 30 June 2019	For the year ended 31 March 2020
Provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS)	-	-	336.48	336.48
Provision on account of certain old unreconciled balances	-	-	350.00	350.00
Provision on account of disputed trade receivables	-	1,766.18	-	1,766.18
Total	-	1,766.18	686.48	2,452.66

- Disclosure of segment-wise information is not applicable, as pathology services is the Company only business segment.
- The figures for the quarter ended 31 March 2020 are derived after taking into account the unaudited financial information for the period of nine months ended 31 December 2019.



- 6 During the quarter, the Company has allotted 51,096 equity shares pursuant to exercise of options under Metropolis Employees Stock Option Scheme 2015 (MESOS 2015). On the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved grant of 2,06,700 Restricted Stock Units (RSU) pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / Subsidiary(ies) during the quarter ended 30 June 2020.
- 7 On 16 January 2020, the Company entered into a Share purchase agreement (SPA) to acquire 51% in Shraddha Diagnostics Centre (India) Private Limited for an aggregate consideration of Rs 936.30 lakhs, within 3 months from date of SPA subject to satisfaction of certain conditions as specified in SPA. On 2 July 2020, the Company decided not to pursue the acquisition on account of non satisfaction of performance conditions by the counter party.
- 8 The Company were operated at sub optimal levels following Government directives on lockdown in Q1'2020-21. While most of the economic activity were at halt during the lockdown period, the healthcare sector continued operations under the Essentials Commodities Act. Accordingly, the Company continued to service customers across channels. After permissions on resumption and relaxations in the lockdown guidance came from mid-April 2020 onwards, the Company witnessed an uptick in demand from customers across various segments. The Company being the first private lab in the country to get approval from ICMR for Covid-19 test however the lockdown has adversely impacted the performance of the Company in the current quarter. The Company has taken into account the account the possible impact of COVID-19 in preparation of the interim consolidated financial results, including but not limited to its assessment of the liquidity and going concern assumptions, recoverable values of its financial assets and non-financial assets, impact on revenues and costs. The impact of Covid-19 on the consolidated financial results may differ from that estimated as at the date of approval of the interim consolidated financial results. The Company is closely monitoring any material changes to future economic situations and any such changes will be prospectively recognized.
- 9 The results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

Metropolis Healthcare Limited


Ameera Shah
Managing Director
DIN : 00208095
Place: Goa
Date: 11 August 2020

TARUN K
KINGER
Digitally signed by
TARUN K KINGER
Date: 2020.08.11
15:02:53 +05'30'

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on unaudited quarterly consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss its joint venture for the quarter ended 30 June 2020 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities as stated in Annexure A

B S R & Co (a partnership firm with
Registration No. BA61223) converted into
B S R & Co. LLP (a Limited Liability Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011, India

**Limited review report on unaudited quarterly consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
(Continued)**

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial information of six (6) subsidiaries which have not been reviewed, whose interim financial information reflect total revenue of Rs. 1,027.89 lakhs, total net profit after tax of Rs. 32.98 lakhs and total comprehensive income of Rs. 185.52 lakhs for the quarter ended 30 June 2020, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022

TARUN K
KINGER

Digitally signed by
TARUN K KINGER
Date: 2020.08.11
14:34:22 +05'30'

Tarun Kinger

Partner

Mumbai
11 August 2020

Membership No: 105003
ICAI UDIN: 20105003AAAACE7445

Annexure -A: List of entities included in the consolidated financial results:

Sr No	Name of Entity	Relationship
1	Sudharma Metropolis Health Services Private Limited	Subsidiary
2	Bokil Golwilkar Metropolis Healthcare Private Limited	Subsidiary
3	Raj Metropolis Healthcare Private Limited	Subsidiary
4	Desai Metropolis Health Services Private Limited	Subsidiary
5	R.V. Metropolis Diagnostics & Healthcare Centre Private Limited	Subsidiary
6	Micron Metropolis Healthcare Private Limited	Subsidiary
7	Dr. Patel Metropolis Healthcare Private Limited	Subsidiary
8	Lab One Metropolis Healthcare Services Private Limited	Subsidiary
9	Amins Pathology Laboratory Private Limited	Subsidiary
10	Ekopath Metropolis Lab Services Private Limited	Subsidiary
11	Metropolis Healthcare Lanka Private Limited	Subsidiary
12	Metropolis Healthcare (Mauritius) Limited	Subsidiary
13	Metropolis Star Lab Kenya Limited	Subsidiary
14	Metropolis Healthcare Ghana Limited	Subsidiary
15	Metropolis Bramser Lab Services (Mtius) Limited	Subsidiary
16	Metropolis Healthcare (Tanzania) Limited	Subsidiary
17	Metropolis Histoexpert Digital Services Private Limited	Joint Venture

Metropolis Healthcare Limited
Registered and Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400030
CIN:L73100MH2000PLC192798
Tel. No.: 022 6258 2810
Email: support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070



Statement of Consolidated Financial Results for the quarter ended 30 June 2020

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Year Ended
		30 June 2020 (Unaudited)	31 March 2020 (Audited) (Refer Note 6)	30 June 2019 (Unaudited)	31 March 2020 (Audited)
1	Income				
	a) Revenue from operations	14,312.84	20,697.45	20,329.63	85,640.54
	b) Other income	315.40	307.12	154.67	856.66
	Total Income	14,628.24	21,004.57	20,484.30	86,497.20
2	Expenses				
	a) Cost of material consumed	3,815.21	5,094.30	4,818.54	20,413.50
	b) Laboratory testing charges	199.54	259.61	154.09	688.99
	c) Employee benefits expense	4,607.44	4,492.05	4,724.26	19,015.62
	d) Finance costs	187.07	227.74	176.18	834.47
	e) Depreciation and amortisation expense	987.77	1,114.42	827.47	3,926.72
	f) Other expenses	4,479.84	5,711.49	5,130.36	22,239.95
	Total Expenses	14,276.87	16,899.61	15,830.90	67,119.25
3	Profit before exceptional items, share of profit for equity accounted investees and income tax (1) - (2)	351.37	4,104.96	4,653.40	19,377.95
4	Exceptional Items (Refer note 4)	-	1,766.18	686.48	2,452.66
5	Profit before share of profit for equity accounted investees and tax (3) - (4)	351.37	2,338.78	3,966.92	16,925.29
6	Share of loss for equity accounted investees (net of tax)	-	-	(32.92)	(51.98)
7	Profit before tax (5) + (6)	351.37	2,338.78	3,934.00	16,873.31
8	Tax expenses				
	Current tax	287.07	1,955.14	1,222.06	5,326.98
	Deferred tax (income) /expense	(160.45)	(876.14)	20.48	(919.33)
	Tax adjustments for earlier years	(63.12)	(289.56)	-	(289.56)
	Total tax expenses	63.50	789.44	1,242.54	4,118.09
9	Profit for the period/year (7) -(8)	287.87	1,549.34	2,691.46	12,755.22
10	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(52.01)	(34.53)	11.59	(208.04)
	Items that will be subsequently reclassified to profit and loss (net of tax)	134.47	(92.67)	10.42	(92.11)
	Other comprehensive income / (loss) for the period /year (net of tax)	82.46	(127.20)	22.01	(300.15)
11	Total comprehensive income (9) + (10)	370.33	1,422.14	2,713.47	12,455.07
12	Profit/ (loss) attributable to:				
	Owners of the Company	290.05	1,549.29	2,678.00	12,732.56
	Non-controlling interest	(2.18)	0.05	13.46	22.66
13	Other comprehensive income / (loss) attributable to:				
	Owners of the Company	82.45	(127.56)	22.09	(300.18)
	Non-controlling interest	0.01	0.36	(0.08)	0.03
14	Total comprehensive income / (loss) attributable to:				
	Owners of the Company	372.50	1,421.74	2,700.09	12,432.37
	Non-controlling interest	(2.17)	0.41	13.38	22.69
15	Paid-up equity share capital (face value - Rs. 2 per share)	1,013.63	1,012.61	1,003.57	1,012.61
16	Other equity (including Non-controlling interest)				52,515.37
17	Earnings per share (Face value of Rs.2 each) basic- (Rs.)	0.57*	3.09*	5.34*	25.36
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)	0.57*	3.07*	5.33*	25.25

Amr



(*not annualised)

See accompanying note to the unaudited consolidated financial results

NOTES:

- 1 These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above unaudited results were reviewed by the Audit Committee at their meeting held on 11 August 2020 and thereafter approved by the Board of Directors at their meeting held on 11 August 2020. The statutory auditors have expressed an unmodified review opinion.
- 3 Metropolis Healthcare Limited (the 'Company' or the 'Parent'), and its subsidiaries (referred to collectively as the 'Group') and its joint venture are primarily involved in providing pathology and related healthcare services

- 4 Exceptional items comprises of: (in Rs Lakhs)

Particulars	For the quarter ended 30 June 2020	For the quarter ended 31 March 2020	For the quarter ended 30 June 2019	For the year ended 31 March 2020
Provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS)	-	-	336.48	336.48
Provision on account of certain old unreconciled balances	-	-	350.00	350.00
Provision on account of disputed trade receivables	-	1,766.18	-	1,766.18
Total	-	1,766.18	686.48	2,452.66

- 5 Disclosure of segment –wise information is not applicable, as pathology services is the Group's only business segment.
- 6 The figures for the quarter ended 31 March 2020 are derived after taking into account the unaudited financial information for the period of nine months ended 31 December 2019.
- 7 During the quarter, the Company has allotted 51,096 equity shares pursuant to exercise of options under Metropolis Employees Stock Option Scheme 2015 "(MESOS 2015)". On the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved grant of 2,06,700 Restricted Stock Units (RSU) pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / Subsidiary(ies) during the quarter ended 30 June 2020.
- 8 On 16 January 2020, the Company entered into a Share purchase agreement (SPA) to acquire 51% in Shraddha Diagnostics Centre (India) Private Limited for an aggregate consideration of Rs 936.30 lakhs, within 3 months from date of SPA subject to satisfaction of certain conditions as specified in SPA. On 2 July 2020, the Company decided not to pursue the acquisition on account of non satisfaction of performance conditions by the counter party.
- 9 The Group were operated at sub optimal levels following Government directives on lockdown in Q1'2020-21. While most of the economic activity were at halt during the lockdown period, the healthcare sector continued operations under the Essentials Commodities Act. Accordingly, the Group continued to service customers across channels. After permissions on resumption and relaxations in the lockdown guidance came from mid-April 2020 onwards, the Group witnessed an uptick in demand from customers across various segments. The Company being the first private lab in the country to get approval from ICMR for Covid-19 test however the lockdown has adversely impacted the performance of the Company in the current quarter. The Group has taken into account the account the possible impact of COVID-19 in preparation of the interim consolidated financial results, including but not limited to its assessment of the liquidity and going concern assumptions, recoverable values of its financial assets and non-financial assets, impact on revenues and costs. The impact of Covid-19 on the consolidated financial results may differ from that estimated as at the date of approval of the interim consolidated financial results. The Group is closely monitoring any material changes to future economic situations and any such changes will be prospectively recognized.
- 10 The results of the Group are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

For Metropolis Healthcare Limited


Anshu Shah
Managing Director
DIN:00208095
Place: Goa
Date: 11 August 2020

TARUN K
KINGER
 Digitally signed
 by TARUN K
 KINGER
 Date: 2020.08.11
 15:02:11 +05'30'

ANNEXURE 2– ACQUISITION OF BALANCE STAKE IN METROPOLIS HISTOXPRT DIGITAL SERVICES PRIVATE LIMITED AND RAJ METROPOLIS HEALTHCARE PRIVATE LIMITED

Sr. No.	Particulars	Details of acquisition	
1	Name of the entity	Metropolis Histoxpert Digital Services Private Limited ('Histoxpert')	Raj Metropolis Healthcare Private Limited ('Raj Metropolis')
2	Whether the proposed acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group Companies have any interest in the entity being acquired?	No. The Promoter / Promoter group does not have any interest in the above transaction.	No. The Promoter / Promoter group does not have any interest in the above transaction.
3	Industry to which the acquired entity belongs	Healthcare	Healthcare
4	Objects and effects of acquisition	To ensure complete control over the affairs of Histoxpert and ensure operational efficiency	To ensure complete control over the affairs of Raj Metropolis and ensure operational efficiency
5	Brief details of any government or regulatory approvals required for the acquisition	No statutory approvals required	No statutory approvals required
6	Indicative time period for completion of acquisition	3 months	3 months
7	Nature of consideration	Cash	Cash
8	Cost of acquisition	Rs. 32,648/-	Rs. 82,33,423/-
9	Percentage of shareholding being acquired	Acquisition of the balance 35% stake in Histoxpert represented by 10,50,000 equity shares of face value Rs. 10 each	Acquisition of the balance 49% stake in Raj Metropolis represented by 8,894 equity shares of face value Rs. 10 each
10	Brief background about the entity being acquired	Refer table below	Refer table below

Brief background about the entity being acquired:

Sr. No.	Particulars	Metropolis Histoxpert Digital Services Private Limited ('Histoxpert')	Raj Metropolis Healthcare Private Limited ('Raj Metropolis')
1	Product / Line of business	Diagnostics business	Diagnostics business
2	Date of Incorporation	February 8, 2018	February 6, 2012
3	Country in which the entity has presence	India	India
4	Last three years turnover (in Rs Lakhs)	2017-18 – NA 2018-19 – Rs 17.44 2019-20 – Rs 41.63	2017-18 -Rs 157.44 2018-19 -Rs 185.53 2019- 20 -Rs 203.48

BLOOD TESTS • DIAGNOSTICS • WELLNESS



Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.